RU2138500C1 - Производные ксантина и их фармакологически переносимые соли - Google Patents

Производные ксантина и их фармакологически переносимые соли Download PDF

Info

Publication number
RU2138500C1
RU2138500C1 RU95109100A RU95109100A RU2138500C1 RU 2138500 C1 RU2138500 C1 RU 2138500C1 RU 95109100 A RU95109100 A RU 95109100A RU 95109100 A RU95109100 A RU 95109100A RU 2138500 C1 RU2138500 C1 RU 2138500C1
Authority
RU
Russia
Prior art keywords
carbon atoms
group
substituted
alkyl
formula
Prior art date
Application number
RU95109100A
Other languages
English (en)
Russian (ru)
Other versions
RU95109100A (ru
Inventor
Кюфнер-Мюль Ульрике
Энзингер Хельмут
Мирау Йоахим
Кун Франц-Йозеф
Лер Эрих
Мюллер Энцио
Original Assignee
Берингер Ингельхайм КГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Ингельхайм КГ filed Critical Берингер Ингельхайм КГ
Publication of RU95109100A publication Critical patent/RU95109100A/ru
Application granted granted Critical
Publication of RU2138500C1 publication Critical patent/RU2138500C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
RU95109100A 1992-08-10 1993-08-05 Производные ксантина и их фармакологически переносимые соли RU2138500C1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4226371 1992-08-10
DEP4226371.9 1992-08-10
DE4238423 1992-11-13
DEP4238423.0 1992-11-13
PCT/EP1993/002077 WO1994003456A1 (de) 1992-08-10 1993-08-05 Unsymmetrisch substituierte xanthine mit adenosinantagonistischen eigenschaften

Publications (2)

Publication Number Publication Date
RU95109100A RU95109100A (ru) 1996-12-27
RU2138500C1 true RU2138500C1 (ru) 1999-09-27

Family

ID=25917371

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95109100A RU2138500C1 (ru) 1992-08-10 1993-08-05 Производные ксантина и их фармакологически переносимые соли

Country Status (21)

Country Link
US (1) US5719279A (https=)
EP (1) EP0654033A1 (https=)
JP (1) JPH08500344A (https=)
KR (1) KR950702988A (https=)
CN (1) CN1043348C (https=)
AU (1) AU681348B2 (https=)
BG (1) BG62618B1 (https=)
CA (1) CA2140883A1 (https=)
CZ (1) CZ286459B6 (https=)
FI (1) FI950542L (https=)
HU (1) HUT65734A (https=)
IL (1) IL106624A (https=)
MX (1) MX9304819A (https=)
NZ (1) NZ254804A (https=)
PL (1) PL176389B1 (https=)
RU (1) RU2138500C1 (https=)
SG (1) SG55038A1 (https=)
SK (1) SK18595A3 (https=)
TW (1) TW252044B (https=)
UA (1) UA46697C2 (https=)
WO (1) WO1994003456A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2269529C2 (ru) * 2000-04-07 2006-02-10 Новартис Аг Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde 5
RU2302420C2 (ru) * 2000-09-19 2007-07-10 Шеринг Корпорейшн Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения
RU2318825C2 (ru) * 2003-05-06 2008-03-10 Си Ви Терапьютикс, Инк. Производные ксантина в качестве антагонистов a2b аденозинового рецептора
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
RU2374247C2 (ru) * 2003-11-21 2009-11-27 Си Ви Терапьютикс, Инк. Способ получения антагонистов аденозиновых рецепторов a2b и промежуточные продукты
EA014684B1 (ru) * 2001-09-06 2010-12-30 Байоджен Айдек Ма Инк. Способы лечения легочных заболеваний
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW252044B (https=) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
EP0799040B1 (en) 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
US6066641A (en) * 1994-12-13 2000-05-23 Euro-Celtique S.A. Aryl thioxanthines
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU4980999A (en) 1998-07-10 2000-02-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor antagonists
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
MXPA02004795A (es) 1999-11-12 2005-07-01 Biogen Inc Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
US7087589B2 (en) 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
MXPA05011371A (es) 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
WO2004110379A2 (en) * 2003-06-09 2004-12-23 Endacea, Inc. A1 adenosine receptor antagonists
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) * 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
JP2010500326A (ja) * 2006-08-08 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
BRPI0815405A2 (pt) * 2007-08-17 2015-02-03 Boehringer Ingelheim Int Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
CA2709772A1 (en) 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
US7928259B2 (en) * 2008-02-12 2011-04-19 Frx Polymers, Inc. Diaryl alkylphosphonates and methods for preparing same
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UA119131C2 (uk) * 2008-08-15 2019-05-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Похідні пурину для застосування при лікуванні пов'язаних із fab захворювань
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP5334511B2 (ja) * 2008-09-22 2013-11-06 日本精化株式会社 化粧料
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CA2755561A1 (en) * 2009-03-26 2010-09-30 Mapi Pharma Limited Process for the preparation of alogliptin
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
RU2643336C1 (ru) * 2016-10-03 2018-01-31 Общество с Ограниченной Ответственностью "Компания "ЭЛТА" СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
CN109796453A (zh) * 2019-02-12 2019-05-24 南京纽邦生物科技有限公司 一种1,7-二甲基黄嘌呤的制备方法
US20240002416A1 (en) 2020-10-15 2024-01-04 Rheinische-Friedrich-Wilhelms-Universität Bonn MRGPRX4 Agonists and Antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1245261A3 (ru) * 1982-07-28 1986-07-15 Адир (Фирма) Способ получени производных ксантина или их аддитивных солей с кислотами
US4605658A (en) * 1983-10-07 1986-08-12 Ceskoslovenska Akademie Ved. Antivirally active adenine derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
DE69130869T2 (de) * 1990-10-18 1999-06-10 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
TW252044B (https=) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1245261A3 (ru) * 1982-07-28 1986-07-15 Адир (Фирма) Способ получени производных ксантина или их аддитивных солей с кислотами
US4605658A (en) * 1983-10-07 1986-08-12 Ceskoslovenska Akademie Ved. Antivirally active adenine derivatives

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2269529C2 (ru) * 2000-04-07 2006-02-10 Новартис Аг Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde 5
RU2302420C2 (ru) * 2000-09-19 2007-07-10 Шеринг Корпорейшн Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения
RU2302420C9 (ru) * 2000-09-19 2008-12-10 Шеринг Корпорейшн Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения
EA014684B1 (ru) * 2001-09-06 2010-12-30 Байоджен Айдек Ма Инк. Способы лечения легочных заболеваний
RU2318825C2 (ru) * 2003-05-06 2008-03-10 Си Ви Терапьютикс, Инк. Производные ксантина в качестве антагонистов a2b аденозинового рецептора
RU2374247C2 (ru) * 2003-11-21 2009-11-27 Си Ви Терапьютикс, Инк. Способ получения антагонистов аденозиновых рецепторов a2b и промежуточные продукты
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность

Also Published As

Publication number Publication date
CZ34895A3 (en) 1995-10-18
IL106624A0 (en) 1993-12-08
SK18595A3 (en) 1995-07-11
PL307397A1 (en) 1995-05-15
BG99489A (bg) 1996-01-31
AU4707193A (en) 1994-03-03
PL176389B1 (pl) 1999-05-31
NZ254804A (en) 1997-01-29
FI950542A0 (fi) 1995-02-08
EP0654033A1 (de) 1995-05-24
HU9302302D0 (en) 1993-10-28
TW252044B (https=) 1995-07-21
WO1994003456A1 (de) 1994-02-17
RU95109100A (ru) 1996-12-27
CZ286459B6 (en) 2000-04-12
FI950542A7 (fi) 1995-02-08
SG55038A1 (en) 1998-12-21
AU681348B2 (en) 1997-08-28
UA46697C2 (uk) 2002-06-17
JPH08500344A (ja) 1996-01-16
CA2140883A1 (en) 1994-02-17
MX9304819A (es) 1994-02-28
US5719279A (en) 1998-02-17
CN1043348C (zh) 1999-05-12
CN1086818A (zh) 1994-05-18
FI950542L (fi) 1995-02-08
IL106624A (en) 1999-01-26
BG62618B1 (bg) 2000-03-31
KR950702988A (ko) 1995-08-23
HUT65734A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
RU2138500C1 (ru) Производные ксантина и их фармакологически переносимые соли
AU2019213425B2 (en) Autotaxin inhibitor compounds
US5470867A (en) Imidazoles and their salts having antagonistic activity to angiotesin II recetors
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
KR100526094B1 (ko) Ｐｄｅ5 저해제로서 8-퀴놀린크산틴 및8-이소퀴놀린크산틴 유도체
OA12147A (en) PyrroloÄ2,3dÜpyrimidine compositions and their use.
EP0201188A2 (en) 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds
JP2003506375A (ja) チロシンタンパク質キナーゼｓｙｋのプリン誘導体阻害剤
CA2674875A1 (en) Purine derivatives
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
EP1911755B1 (en) Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
MX2008015954A (es) 8-[6-amino-3-piridil]xantinas sustituidas.
EP0112142A2 (en) Pyridine derivatives
US6878716B1 (en) Compounds specific to adenosine A1 receptor and uses thereof
RU2295525C2 (ru) Амидозамещенные производные ксантина, обладающие ингибирующим действием фосфоенолпируваткарбоксикиназы (фепкк), способ их получения, фармацевтическая композиция и применение
CN1219936A (zh) 新的三唑并嘌呤、其制备方法及其作为药品的用途
DE4325254A1 (de) Unsymmetrisch substituierte Xanthine
US20090143375A1 (en) Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents
HU194895B (en) Process for production of new pyrimide /2,1-b/ benzothiasoles and medical preparatives containing these substances
MX2008000657A (es) Compuesto benzoimidazol capaz de inhibir prostaglandina d sintetasa.